NHS England says new guidance has been drawn up to encourage doctors to place mental health therapists in practice surgeries, to bring mental and physical health services “under one roof”.
News
NICE says ‘no’ to Gilead’s Yescarta in draft guidelines
NHS funding for Gilead’s freshly approved CAR-T therapy Yescarta has been turned down in draft guidelines by the National Institute for Health and Care Excellence.
Bayer, J&J’s Xarelto fails to hit PhIII targets
Bayer and Johnson & Johnson’s plans to expand the scope of blood thinner Xarelto have hit a setback after the drug failed to hit targets in two studies in venous thromboembolism and heart failure studies.
Bayer files marketing application for larotrectinib
Bayer has filed a marketing application in Europe seeking approval for larotrectinib as treatment for TRK fusion cancer.
EU approves first CAR-T therapies
European regulators have approved Novartis’ Kymriah and Gilead’s Yescarta, enabling patients to access CAR-T therapies across the region for the first time.
FDA rejects Akcea/Ionis’ rare disease drug Waylivra
US regulators have rejected Akcea/Ionis’ application to market Waylivra for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Sales Awards: Less than two weeks left to enter – do it today
The all new Sales Awards will take place at The Tower Hotel, London on Thursday 15 November, alongside the Communications Team of the Year Awards and the 25th anniversary of Marketer of the Year. With the competition closing for entry in just two weeks and spaces filling up fast, PharmaTimes Media is calling on prospective candidates to reserve their places now to avoid missing out.
Communications Team of the Year: Nearly fully booked
Seize the opportunity to show off your skills and abilities as an agency in the Communications Team of the Year competition. With just one space left in the International Challenge, one in the NHS Challenge and limited availability in the Charity Challenge, agencies wishing to take part should reserve their place now to avoid missing out.
Marketer of the Year: Develop your skills and fulfil your potential
Marketer of the Year will celebrate its 25th anniversary at The Tower Hotel, London on Thursday 15 November, alongside Communications Team of the Year and the all-new Sales Awards. Designed to both assess and reward the competencies and potential of pharma marketers, the Marketer of the Year competition identifies and benchmarks marketing talent within pharma organisations against the wider industry.
Eisai/MSD’s Lenvima approved in Europe for liver cancer
Eisai and MSD’s Lenvima has won approval in the EU as a first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Roche signs inclacumab deal with GBT
Roche has sold off rights to inclacumab to Global Blood Therapeutics, which intends to develop the treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD).
US clears new treatment option for Dravet syndrome
US regulators have approved Biocodex’ Diacomit for the treatment of seizures associated with Dravet syndrome (DS), a rare and difficult to treat form of epilepsy.
Gov’t asks drugmakers to stockpile meds for Brexit
The government has asked drug manufacturers to increase stockpiles of medicines to ensure continued supply in the event that the UK leaves the EU in a ‘no-deal’ scenario.
Shire’s HAE drug Takhzyro gets green light in the US
Shire’s Takhzyro has been approved in the US for the prevention of attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
Mallinckrodt’s stannsoporfin turned away by FDA
US regulators have rejected an application by Mallinckrodt to market stannsoporfin for newborns at risk of jaundice.
